TITLE

Stockholders protest Pfizer's drug prices

AUTHOR(S)
Lenzer, Jeanne
PUB. DATE
July 2004
SOURCE
CMAJ: Canadian Medical Association Journal;7/6/2004, Vol. 171 Issue 1, p24
SOURCE TYPE
Academic Journal
DOC. TYPE
journal article
ABSTRACT
Reports on the criticism of the Interfaith Center on Corporate Responsibility (ICCR) against the pricing practices of a number of drug companies. Proposal on drug access submitted by ICCR at Pfizer's annual meeting in 2004; Statement from Adrian Dominican Sisters' coordinator Margaret Weber about the proposal; Position of Pfizer chairman Henry A. McKinnell Jr. regarding the ICCR proposal; Contributions of Pfizer to political action committee and campaign funds.
ACCESSION #
13605112

 

Related Articles

  • Pfizer takes leading role in drug-price debate. Arnold, Matthew // Medical Marketing & Media;Aug2004, Vol. 39 Issue 8, p32 

    Reports on the launch of Helpful Answer, the brand for beefed-up roster of patient assistance programs by Pfizer Inc. in the U.S. Effort of the pharmaceutical industry to alleviate the high cost of drugs to uninsured Americas; Leadership role of Pfizer Inc. in drug-price debate; Expansion of the...

  • Health care industry collaboration can keep drug coverage affordable. Gunza, Rich // New Hampshire Business Review;07/14/2000, Vol. 22 Issue 16, p9 

    Comments on the issue of rising drug costs in the United States. Health care crisis facing the country; Prescription drugs making up 12% of all national health care expenditures; Annual increases in the cost of pharmacy care for health insurers; Need for pharmaceutical companies to collaborate...

  • Don't Fall Asleep Monitoring Rx Coverage--You May Wake Up to a Nightmare. Cahn, Linda // Benefits Magazine;Dec2015, Vol. 52 Issue 12, p34 

    The article discusses the cost challenges and key contract terms that plans should address to control plan costs in the pharmaceutical industry. Topics discussed include the increases in prices of drugs, the entrance of new brand drugs, and concerns on newly approved specialty drugs. Also...

  • Public address. Kelly, Patrick // Medical Marketing & Media;May2004, Vol. 39 Issue 5, p12 

    Reports that Pfizer president Patrick Kelly responded when "The Wall Street Journal" accused pharmaceutical companies of price increases that would wipe out gains in pharmaceutical benefits for low-income seniors covered by Medicare. Kelly's contention that the article gave a distorted view of...

  • Medicaid plans target prescription drug costs.  // Drug Store News;2/18/2002, Vol. 24 Issue 2, p1 

    Reports on the plan of Medicaid to deal with prescription drug costs in the U.S. Problems facing Medicaid; Cost effectiveness of the plan; Increase in drug prices; Implications of the plan.

  • Patients' attempts to cut medication costs.  // Pharmacy Today;Apr2015, Vol. 21 Issue 4, p13 

    Statistics are given regarding the measures taken by patients to cut their medication costs which include buying of prescription drugs from foreign countries, use of alternative therapies, and demand for cheap medication to doctors.

  • Taming Out-of-Control Specialty Pharmaceutical Costs. Palma, Steve // Benefits & Compensation Digest;May2010, Vol. 47 Issue 5, p1 

    The article discusses the state of the U.S. pharmaceutical industry in 2010. It states that though many drugs have been developed that have mitigated previously untreatable diseases, the costs involved are staggering. As a result, healthcare has become equally expensive for private, corporate,...

  • A healthy decision.  // BusinessToday;Aug2015, Issue 201, p1 

    The article focuses on the steps taken by the government of Oman to reduce the cost in healthcare. Topics discussed include revision and reduction in prices of drugs from five therapeutic groups, including gastrointestinal, cardiovascular, and dermatology drugs, to prevent the increase in...

  • Rising Health Care Costs and Life-Cycle Management in the Pharmaceutical Market. Kesselheim, Aaron S. // PLoS Medicine;Jun2013, Vol. 10 Issue 6, p1 

    The author discusses research on rising prescription drug costs. He references the study "Patented Drug Extension Strategies in Healthcare Spending: A Cost-Evaluation Analysis" by Nathalie Vernaz and colleagues published in the journal in 2013. He believes that addressing life-cycle management...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics